Clinical Trial Update: A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type [Phase 3]

View source ↗

Summary

A 12-week extension trial evaluated the safety and tolerability of brexpiprazole for agitation associated with Alzheimer's-type dementia (Alzheimer's disease) i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• brexpiprazole (brexpiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-11-14